Showing results (2291-2300 of 3,030) with videos related to
Sort By:
Pageof 303
Current Pharmaceutical Biotechnology|July 12, 2011
Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progressBalveen Kaur, E Antonio Chiocca, Timothy P CripeCurrent Pharmaceutical Biotechnology|July 12, 2011
Targeted oncolytic herpes simplex viruses for aggressive cancersJennifer Wong, Cleo Lee, Kevin Zhang, et al.Current Pharmaceutical Biotechnology|July 12, 2011
Synergistic interaction of telomerase-specific oncolytic virotherapy and chemotherapeutic agents for human cancerToshiyoshi Fujiwara, Shunsuke Kagawa, Hiroshi TazawaCurrent Pharmaceutical Biotechnology|July 12, 2011
Recent clinical experience with oncolytic virusesO G Donnelly, F Errington-Mais, R Prestwich, et al.Current Pharmaceutical Biotechnology|July 12, 2011
The role of "eye platelet rich plasma" (E-PRP) for wound healing in ophthalmologyJorge L Alio, Francisco Arnalich-Montiel, Alejandra E RodriguezCurrent Pharmaceutical Biotechnology|July 12, 2011
Platelet concentrates for topical use: bedside device and blood transfusion technology. Quality and versatilityPiero Borzini, Valeria Balbo, Laura MazzuccoCurrent Pharmaceutical Biotechnology|July 12, 2011
In search of a consensus terminology in the field of platelet concentrates for surgical use: platelet-rich plasma (PRP), platelet-rich fibrin (PRF), fibrin gel polymerization and leukocytesDavid M Dohan Ehrenfest, Tomasz Bielecki, Allan Mishra, et al.Current Pharmaceutical Biotechnology|May 31, 2011
TGF-β receptor signaling pathways in angiogenesis; emerging targets for anti-angiogenesis therapyLaurens A van Meeteren, Marie-José Goumans, Peter ten DijkeCurrent Pharmaceutical Biotechnology|May 31, 2011
The antisense oligonucleotide trabedersen (AP 12009) for the targeted inhibition of TGF-β2Frank Jaschinski, Tanja Rothhammer, Piotr Jachimczak, et al.Current Pharmaceutical Biotechnology|April 7, 2011
Curcumin and liver cancer: a reviewAltaf S Darvesh, Bharat B Aggarwal, Anupam BishayeePageof 303